LATEST NEWS

 

 

LATEST NEWS

SYNSIGHT IS SELECTED for the Medicen Paris Region Prize!

Two days ago, Biolabs announced the six selected companies for their Masterclass program. SYNSIGHT founders will be participating in the 2021 Masterclass program organized by BioLabs and Servier ! A good chance to meet their team in Boston ! And in addition to being...

read more

SYNSIGHT IS SELECTED IN SPRING50

SYNSIGHT is selected in 2021 SPRING 50 selection, 50 most innovative and promising start-ups in the Paris-Saclay Innovation Playground ecosystem What is spring50 This is a selection that annually honors 50 start-ups from the Paris-Saclay cluster that are the most...

read more

SYNSIGHT In “communications biology”

Lin28, a major translation reprogramming factor, gains access to YB-1-packaged mRNA through its cold-shock domain Abstract The RNA-binding protein Lin28 (Lin28a) is an important pluripotency factor that reprograms translation and promotes cancer progression. Although...

read more

SYNSIGHT & SERVIER

SYNSIGHT founders talk about the close relationship with the Servier team for the Pharma Day on July 8, 2020. TRANSLATION The robustness of the Synsight technology has enabled the Servier team to make possible a much wider application in several therapeutic projects...

read more

INVEST4BIOTECH

SYNSIGHT presents its activity to the 1st edition of Invest4biotech at Genopole among 12 start-ups. SYNSIGHT introduces its innovative drug discovery platform, which combines artificial intelligence, experimental, and computer-aided drug design to financial sponsors.

read more